KR20130004296A - 시클로프로필 아미드 유도체의 제조 방법 및 그와 관련된 중간체 - Google Patents
시클로프로필 아미드 유도체의 제조 방법 및 그와 관련된 중간체 Download PDFInfo
- Publication number
- KR20130004296A KR20130004296A KR20127024174A KR20127024174A KR20130004296A KR 20130004296 A KR20130004296 A KR 20130004296A KR 20127024174 A KR20127024174 A KR 20127024174A KR 20127024174 A KR20127024174 A KR 20127024174A KR 20130004296 A KR20130004296 A KR 20130004296A
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- compound
- reacting
- jacket
- prepared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 44
- 239000000543 intermediate Substances 0.000 title abstract description 10
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical class NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 title abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 150000001875 compounds Chemical class 0.000 claims description 80
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 25
- -1 alkyl phosphono acetate Chemical compound 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical group C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 9
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 8
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 8
- 239000012190 activator Substances 0.000 claims description 7
- 239000003638 chemical reducing agent Substances 0.000 claims description 7
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical group OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 6
- 229910052751 metal Inorganic materials 0.000 claims description 6
- 239000002184 metal Substances 0.000 claims description 6
- MXQOYLRVSVOCQT-UHFFFAOYSA-N palladium;tritert-butylphosphane Chemical group [Pd].CC(C)(C)P(C(C)(C)C)C(C)(C)C.CC(C)(C)P(C(C)(C)C)C(C)(C)C MXQOYLRVSVOCQT-UHFFFAOYSA-N 0.000 claims description 6
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- SHQSVMDWKBRBGB-UHFFFAOYSA-N cyclobutanone Chemical compound O=C1CCC1 SHQSVMDWKBRBGB-UHFFFAOYSA-N 0.000 claims description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 5
- PXACTUVBBMDKRW-UHFFFAOYSA-M 4-bromobenzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-M 0.000 claims description 4
- SPXOTSHWBDUUMT-UHFFFAOYSA-M 4-nitrobenzenesulfonate Chemical compound [O-][N+](=O)C1=CC=C(S([O-])(=O)=O)C=C1 SPXOTSHWBDUUMT-UHFFFAOYSA-M 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims description 3
- 239000003929 acidic solution Substances 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 3
- 150000002978 peroxides Chemical class 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 claims description 2
- 229910000342 sodium bisulfate Inorganic materials 0.000 claims description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical group [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims 2
- 102000004384 Histamine H3 receptors Human genes 0.000 abstract description 7
- 108090000981 Histamine H3 receptors Proteins 0.000 abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 47
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 42
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 40
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 38
- 238000006243 chemical reaction Methods 0.000 description 38
- 239000000243 solution Substances 0.000 description 32
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 29
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 24
- 239000012071 phase Substances 0.000 description 22
- 239000002904 solvent Substances 0.000 description 22
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 18
- 239000012074 organic phase Substances 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 17
- 239000000047 product Substances 0.000 description 16
- 239000011541 reaction mixture Substances 0.000 description 15
- 229960004592 isopropanol Drugs 0.000 description 14
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 235000019253 formic acid Nutrition 0.000 description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- 239000008346 aqueous phase Substances 0.000 description 10
- 238000001035 drying Methods 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- 238000011049 filling Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000012066 reaction slurry Substances 0.000 description 6
- 239000002002 slurry Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000009466 transformation Effects 0.000 description 5
- HCQNNQFCUAGJBD-UHFFFAOYSA-N 1-(4-bromophenyl)-2-chloroethanone Chemical compound ClCC(=O)C1=CC=C(Br)C=C1 HCQNNQFCUAGJBD-UHFFFAOYSA-N 0.000 description 4
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229960001340 histamine Drugs 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- CETVQRFGPOGIQJ-UHFFFAOYSA-N lithium;hexane Chemical compound [Li+].CCCCC[CH2-] CETVQRFGPOGIQJ-UHFFFAOYSA-N 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- DAZXVJBJRMWXJP-UHFFFAOYSA-N n,n-dimethylethylamine Chemical compound CCN(C)C DAZXVJBJRMWXJP-UHFFFAOYSA-N 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- DATRVIMZZZVHMP-MRVPVSSYSA-N tert-butyl (2r)-2-methylpiperazine-1-carboxylate Chemical compound C[C@@H]1CNCCN1C(=O)OC(C)(C)C DATRVIMZZZVHMP-MRVPVSSYSA-N 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000000844 transformation Methods 0.000 description 3
- GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 3
- DPBUJVBXRABXRH-BDAKNGLRSA-N (1s,2s)-2-(4-bromophenyl)cyclopropane-1-carboxylic acid Chemical compound OC(=O)[C@H]1C[C@@H]1C1=CC=C(Br)C=C1 DPBUJVBXRABXRH-BDAKNGLRSA-N 0.000 description 2
- NNINSLOEPXEZOZ-QMMMGPOBSA-N (2r)-2-(4-bromophenyl)oxirane Chemical compound C1=CC(Br)=CC=C1[C@H]1OC1 NNINSLOEPXEZOZ-QMMMGPOBSA-N 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- WJJKCJYVIICABH-UHFFFAOYSA-N 1-cyclobutylpiperazine Chemical compound C1CCC1N1CCNCC1 WJJKCJYVIICABH-UHFFFAOYSA-N 0.000 description 2
- 235000002567 Capsicum annuum Nutrition 0.000 description 2
- 240000004160 Capsicum annuum Species 0.000 description 2
- 235000001258 Cinchona calisaya Nutrition 0.000 description 2
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000011903 deuterated solvents Substances 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000012847 fine chemical Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000004896 high resolution mass spectrometry Methods 0.000 description 2
- 239000003382 histamine H3 receptor agonist Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000003921 particle size analysis Methods 0.000 description 2
- 239000003444 phase transfer catalyst Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229960000948 quinine Drugs 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 2
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 2
- IPILPUZVTYHGIL-UHFFFAOYSA-M tributyl(methyl)azanium;chloride Chemical compound [Cl-].CCCC[N+](C)(CCCC)CCCC IPILPUZVTYHGIL-UHFFFAOYSA-M 0.000 description 2
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- NGBKYBZRHPFKQX-QMMMGPOBSA-N (1r)-1-(4-bromophenyl)-2-chloroethanol Chemical compound ClC[C@H](O)C1=CC=C(Br)C=C1 NGBKYBZRHPFKQX-QMMMGPOBSA-N 0.000 description 1
- DGZFVQNUIORJCE-BDAKNGLRSA-N (1s,2s)-2-(4-carbamoylphenyl)cyclopropane-1-carboxylic acid Chemical compound C1=CC(C(=O)N)=CC=C1[C@@H]1[C@@H](C(O)=O)C1 DGZFVQNUIORJCE-BDAKNGLRSA-N 0.000 description 1
- FTHLUIBYGIBEIZ-ZJUUUORDSA-N (1s,2s)-2-(4-cyanophenyl)cyclopropane-1-carboxylic acid Chemical compound OC(=O)[C@H]1C[C@@H]1C1=CC=C(C#N)C=C1 FTHLUIBYGIBEIZ-ZJUUUORDSA-N 0.000 description 1
- NKLGCRIHUWGUGL-MRVPVSSYSA-N (3r)-1-cyclobutyl-3-methylpiperazine Chemical compound C1CN[C@H](C)CN1C1CCC1 NKLGCRIHUWGUGL-MRVPVSSYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- NLOIIDFMYPFJKP-UHFFFAOYSA-L 1-benzyl-4-(1-benzylpyridin-1-ium-4-yl)pyridin-1-ium;dichloride Chemical compound [Cl-].[Cl-].C=1C=C(C=2C=C[N+](CC=3C=CC=CC=3)=CC=2)C=C[N+]=1CC1=CC=CC=C1 NLOIIDFMYPFJKP-UHFFFAOYSA-L 0.000 description 1
- VCQZCDSEWSFTPO-DLBZAZTESA-N 4-[(1r,2r)-2-(4-cyclobutylpiperazine-1-carbonyl)cyclopropyl]benzamide Chemical compound C1=CC(C(=O)N)=CC=C1[C@H]1[C@H](C(=O)N2CCN(CC2)C2CCC2)C1 VCQZCDSEWSFTPO-DLBZAZTESA-N 0.000 description 1
- VCQZCDSEWSFTPO-SJORKVTESA-N 4-[(1s,2s)-2-(4-cyclobutylpiperazine-1-carbonyl)cyclopropyl]benzamide Chemical compound C1=CC(C(=O)N)=CC=C1[C@@H]1[C@@H](C(=O)N2CCN(CC2)C2CCC2)C1 VCQZCDSEWSFTPO-SJORKVTESA-N 0.000 description 1
- NJJBLDDRYMCIMQ-XWIAVFTESA-N 4-[(1s,2s)-2-[(2r)-4-cyclobutyl-2-methylpiperazine-1-carbonyl]cyclopropyl]benzamide Chemical compound C1([C@H]2C[C@@H]2C(=O)N2CCN(C[C@H]2C)C2CCC2)=CC=C(C(N)=O)C=C1 NJJBLDDRYMCIMQ-XWIAVFTESA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000007527 Autoreceptors Human genes 0.000 description 1
- 108010071131 Autoreceptors Proteins 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 229940115480 Histamine H3 receptor antagonist Drugs 0.000 description 1
- 229940122931 Histamine H3 receptor inverse agonist Drugs 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000037011 constitutive activity Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- RAFFPNRMOQNLAA-MNOVXSKESA-N ethyl (1s,2s)-2-(4-bromophenyl)cyclopropane-1-carboxylate Chemical compound CCOC(=O)[C@H]1C[C@@H]1C1=CC=C(Br)C=C1 RAFFPNRMOQNLAA-MNOVXSKESA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- CTSAXXHOGZNKJR-UHFFFAOYSA-N methyl 2-diethoxyphosphorylacetate Chemical compound CCOP(=O)(OCC)CC(=O)OC CTSAXXHOGZNKJR-UHFFFAOYSA-N 0.000 description 1
- SIGOIUCRXKUEIG-UHFFFAOYSA-N methyl 2-dimethoxyphosphorylacetate Chemical compound COC(=O)CP(=O)(OC)OC SIGOIUCRXKUEIG-UHFFFAOYSA-N 0.000 description 1
- OUAUEIYYLHUEPK-UHFFFAOYSA-M methyl sulfate;1,2,3-trimethylimidazol-1-ium Chemical compound COS([O-])(=O)=O.CC=1N(C)C=C[N+]=1C OUAUEIYYLHUEPK-UHFFFAOYSA-M 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- BDOLXPFAFMNDOK-UHFFFAOYSA-N oxazaborolidine Chemical compound B1CCON1 BDOLXPFAFMNDOK-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000004714 phosphonium salts Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 239000002469 receptor inverse agonist Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000000956 solid--liquid extraction Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- IBWGNZVCJVLSHB-UHFFFAOYSA-M tetrabutylphosphanium;chloride Chemical compound [Cl-].CCCC[P+](CCCC)(CCCC)CCCC IBWGNZVCJVLSHB-UHFFFAOYSA-M 0.000 description 1
- WAGFXJQAIZNSEQ-UHFFFAOYSA-M tetraphenylphosphonium chloride Chemical compound [Cl-].C1=CC=CC=C1[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WAGFXJQAIZNSEQ-UHFFFAOYSA-M 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 238000009901 transfer hydrogenation reaction Methods 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/06—Preparation of carboxylic acid amides from nitriles by transformation of cyano groups into carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/14—Preparation of carboxylic acid amides by formation of carboxamide groups together with reactions not involving the carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Epoxy Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30558310P | 2010-02-18 | 2010-02-18 | |
| US61/305,583 | 2010-02-18 | ||
| PCT/SE2011/050171 WO2011102794A1 (en) | 2010-02-18 | 2011-02-17 | Processes for making cyclopropyl amide derivatives and intermediates associated therewith |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20130004296A true KR20130004296A (ko) | 2013-01-09 |
Family
ID=44370080
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR20127024174A Withdrawn KR20130004296A (ko) | 2010-02-18 | 2011-02-17 | 시클로프로필 아미드 유도체의 제조 방법 및 그와 관련된 중간체 |
| KR20127021548A Withdrawn KR20130002316A (ko) | 2010-02-18 | 2011-02-17 | 시클로프로필 벤즈아미드 유도체의 신규 결정질 형태 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR20127021548A Withdrawn KR20130002316A (ko) | 2010-02-18 | 2011-02-17 | 시클로프로필 벤즈아미드 유도체의 신규 결정질 형태 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20110201623A1 (enExample) |
| EP (2) | EP2536685B1 (enExample) |
| JP (3) | JP2013520413A (enExample) |
| KR (2) | KR20130004296A (enExample) |
| CN (2) | CN102869651A (enExample) |
| AR (2) | AR080204A1 (enExample) |
| AU (2) | AU2011218491C1 (enExample) |
| BR (2) | BR112012020629A2 (enExample) |
| CA (2) | CA2790040A1 (enExample) |
| CL (2) | CL2012002259A1 (enExample) |
| CO (1) | CO6592109A2 (enExample) |
| ES (1) | ES2541857T3 (enExample) |
| IL (1) | IL221431A (enExample) |
| MX (2) | MX2012009473A (enExample) |
| NZ (2) | NZ602110A (enExample) |
| RU (2) | RU2012136148A (enExample) |
| SG (3) | SG182732A1 (enExample) |
| TW (2) | TWI520945B (enExample) |
| WO (2) | WO2011102794A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2253615B1 (en) | 2007-08-22 | 2014-07-09 | AstraZeneca AB | Cyclopropyl amide derivatives |
| TW201039825A (en) | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
| JP5746718B2 (ja) * | 2010-02-18 | 2015-07-08 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | シクロプロピルアミド誘導体からなる固体形態 |
| US20110201623A1 (en) * | 2010-02-18 | 2011-08-18 | Uczynski Michael A | Crystalline Form Of A Cyclopropyl Benzamide Derivative |
| KR102256770B1 (ko) * | 2013-03-22 | 2021-05-26 | 메르크 파텐트 게엠베하 | 유기 전계발광 소자용 재료의 제조를 위한 합성 빌딩 블록 |
| FR3003466B1 (fr) * | 2013-03-22 | 2015-08-07 | Servier Lab | Utilisation du 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide pour le traitement des douleurs neuropathiques |
| CN103342655A (zh) * | 2013-07-02 | 2013-10-09 | 扬州大学 | 取代乙二酮双苯胺希夫碱合成取代酰胺的新方法 |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE637271A (enExample) | 1963-04-04 | 1900-01-01 | ||
| NL128365C (enExample) | 1963-11-05 | |||
| US3449427A (en) * | 1965-06-03 | 1969-06-10 | Smithkline Corp | Aminocyclopropane derivatives of 5h-dibenzo(a,d)cycloheptenes |
| US3697506A (en) * | 1970-08-07 | 1972-10-10 | Pfizer | Crystalline alkali metal salts of {60 -carboxybenzylpenicillin and process therefor |
| US3686335A (en) * | 1970-12-21 | 1972-08-22 | Smith Kline French Lab | 5-vinyl-5h-di benzo(a,d)cycloheptenes |
| US4432987A (en) * | 1982-04-23 | 1984-02-21 | Pfizer Inc. | Crystalline benzenesulfonate salts of sultamicillin |
| US4547505A (en) * | 1983-03-25 | 1985-10-15 | Degussa Aktiengesellschaft | N-Phenyl-N-'-cycloalkylalkanoylpiperazine useful as analgetics and process for its production |
| CS244821B2 (en) | 1983-06-16 | 1986-08-14 | Boehringer Ingelheim Ltd | Production method of new substituted phenylalkyl(piperazinyl or homopiperazinyle)-prpylureas or thioureas |
| DE3418167A1 (de) | 1984-05-16 | 1985-11-21 | Bayer Ag, 5090 Leverkusen | Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen heteroaryloxyacetamiden |
| DE3600288A1 (de) | 1986-01-08 | 1987-07-16 | Bayer Ag | Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen sulfonylharnstoff-derivaten |
| DE3618004A1 (de) | 1986-05-28 | 1987-12-03 | Bayer Ag | Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen sulfonyliso(thio)-harnstoff-derivaten |
| CA2071897A1 (en) | 1989-12-28 | 1991-06-29 | Richard A. Glennon | Sigma receptor ligands and the use thereof |
| EP0435320B1 (en) * | 1989-12-29 | 1994-10-05 | Banyu Pharmaceutical Co., Ltd. | 2(2-Cyclopropylpyrrolidin-4-ylthio)-carbapenem derivatives |
| DE69227778T2 (de) | 1991-08-22 | 1999-07-01 | Monsanto Co., St. Louis, Mo. | Safener für herbizide pyrazolylsulfonylharnstoffe |
| DE4131139A1 (de) * | 1991-09-19 | 1993-03-25 | Bayer Ag | Verfahren zur herstellung von 1-fluor-cyclopropan-1-carbonsaeure |
| DE69427469T2 (de) * | 1993-03-12 | 2001-10-31 | Pharmacia & Upjohn Co., Kalamazoo | Kristallines ceftiofur (freie säure) |
| CA2205998C (en) | 1994-11-23 | 2002-07-16 | Neurogen Corporation | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands |
| US5604253A (en) | 1995-05-22 | 1997-02-18 | Merck Frosst Canada, Inc. | N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors |
| US5859246A (en) | 1997-01-30 | 1999-01-12 | Neurogen Corporation | 1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands |
| JP3476203B2 (ja) | 1997-02-24 | 2003-12-10 | ザイモジュネティックス インコーポレイテッド | カルシトニン擬似体 |
| US6160134A (en) | 1997-12-24 | 2000-12-12 | Bristol-Myers Squibb Co. | Process for preparing chiral cyclopropane carboxylic acids and acyl guanidines |
| KR20010034442A (ko) | 1998-01-27 | 2001-04-25 | 아벤티스 파마슈티칼즈 프로덕츠 인코포레이티드 | 치환된 옥소아자헤테로사이클릴 인자 Ｘａ 억제제 |
| US6268367B1 (en) | 1998-02-23 | 2001-07-31 | Zymogenetics, Inc. | Piperazine derivatives for treating bone deficit conditions |
| EP1090919A4 (en) * | 1998-06-26 | 2002-05-22 | Chugai Pharmaceutical Co Ltd | L-ALPHA-AMINOADIPIC ACID DERIVATIVE IN FINE POWDER, ORAL SOLID PREPARATIONS CONTAINING SAID DERIVATIVE AND BULK POWDER PROCESSING PROCESS |
| US6284761B1 (en) * | 1999-01-08 | 2001-09-04 | Neurogen Corporation | 1-phenyl-4-(1-[2-aryl]cyclopropyl)methylpiperazines: dopamine receptor ligands |
| WO2000040572A1 (en) | 1999-01-08 | 2000-07-13 | Neurogen Corporation | 1-phenyl-4-(1-[2-aryl]cyclopropyl) methylpiperazines: dopamine receptor ligands |
| GB9913083D0 (en) * | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| AU5426500A (en) | 1999-06-16 | 2001-01-02 | Takeda Chemical Industries Ltd. | Benzazepine derivatives, process for the preparation of the same and uses thereof |
| WO2001022963A1 (en) | 1999-09-27 | 2001-04-05 | Merck & Co., Inc. | Method of preventing osteoporosis |
| IL150524A0 (en) * | 2000-01-07 | 2003-02-12 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| US6521619B2 (en) | 2000-06-29 | 2003-02-18 | Icos Corporation | Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents |
| CA2414464A1 (en) | 2000-06-29 | 2002-01-10 | Abbott Laboratories | Aryl phenycyclopropyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
| JP2004525071A (ja) | 2000-07-20 | 2004-08-19 | ニューロジェン コーポレイション | カプサイシン受容体リガンド |
| WO2002051781A1 (fr) | 2000-12-25 | 2002-07-04 | Ajinomoto Co., Inc. | Procede permettant de preparer un compose d'halohydrine optiquement actif |
| US7053089B2 (en) * | 2001-02-23 | 2006-05-30 | Merck & Co., Inc. | N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists |
| EP1763350B1 (en) | 2004-07-06 | 2011-12-21 | Xenon Pharmaceuticals Inc. | Nicotinamide derivatives and their use as therapeutic agents |
| EP1421071B1 (en) | 2001-07-02 | 2009-11-18 | High Point Pharmaceuticals, LLC | Substituted piperazine and diazepane derivaives as histamine h3 receptor modulators |
| CA2456754A1 (en) | 2001-08-08 | 2003-02-20 | Yuji Iizawa | Benzazepine derivative, process for producing the same, and use |
| WO2003026572A2 (en) | 2001-09-26 | 2003-04-03 | Merck & Co., Inc. | Crystalline forms of ertapenem sodium |
| WO2003037271A2 (en) | 2001-10-30 | 2003-05-08 | Millennium Pharmaceuticals,Inc. | Compounds, pharmaceutical compositions and methods of use therefor |
| US6861432B2 (en) * | 2001-11-23 | 2005-03-01 | Schering Aktiengesellschaft | Piperazine derivatives that destabilize androgen receptors |
| KR20030076445A (ko) * | 2002-03-22 | 2003-09-26 | 주식회사 엘지생명과학 | (2Ｓ)-Ｎ-[5-[아미노(이미노)메틸]-2-티에닐]메틸-1-[(2Ｒ)-2-[(카복시메틸)아미노]-3,3-디페닐프로파노일]-2-피롤리딘카르복사미드ㆍｎＨ2Ｏ의 새로운 결정형 |
| WO2003103666A2 (en) | 2002-06-07 | 2003-12-18 | Altana Pharma Ag | Novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones |
| US20040209858A1 (en) * | 2002-10-22 | 2004-10-21 | Bennani Youssef L. | Cycloalkylamides and their therapeutic applications |
| US20040077618A1 (en) * | 2002-10-22 | 2004-04-22 | Bennani Youssef L. | Cycloalkylamides and their therapeutic applications |
| AU2003284402A1 (en) | 2002-11-15 | 2004-06-15 | Yamanouchi Pharmaceutical Co., Ltd. | Antagonist to melanin-concentrating hormone receptor |
| JP2006514950A (ja) | 2002-12-13 | 2006-05-18 | スミスクライン ビーチャム コーポレーション | Ｃｃｒ５拮抗薬としてのシクロプロピル化合物 |
| TW200503713A (en) * | 2003-04-23 | 2005-02-01 | Glaxo Group Ltd | Novel compounds |
| UA81668C2 (en) | 2003-05-01 | 2008-01-25 | Бристол-Майерс Сквибб Компани | Normal;heading 1;heading 2;ARYL-SUBSTITUTED PYRAZOLE-AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS |
| AR045595A1 (es) | 2003-09-04 | 2005-11-02 | Vertex Pharma | Composiciones utiles como inhibidores de proteinas quinasas |
| RU2006125441A (ru) | 2003-12-15 | 2008-01-27 | Джапан Тобакко Инк. (Jp) | Производные циклопропана и их фармацевтическое применение |
| TW200621760A (en) | 2004-09-09 | 2006-07-01 | Mitsubishi Pharma Corp | 2-morpholino-4-pyrimidone compound |
| EP1805164B9 (en) | 2004-09-29 | 2011-09-07 | Mitsubishi Tanabe Pharma Corporation | 6-(pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors |
| ES2303280T3 (es) | 2004-10-15 | 2008-08-01 | Glaxo Group Limited | Derivados de pirrolidina como ligandos de receptores de histamina. |
| WO2006071730A1 (en) | 2004-12-27 | 2006-07-06 | Astrazeneca Ab | Pyrazolone compounds as metabotropic glutamate receptor agonists for the treatment of neurological and psychiatric disorders |
| EP1844052A1 (en) * | 2005-01-26 | 2007-10-17 | Pharmacia & Upjohn Company LLC | Thieno[2,3-d]pyrimidine compounds as inhibitors of adp-mediated platelets aggregation |
| WO2006087169A1 (en) * | 2005-02-15 | 2006-08-24 | Glaxo Group Limited | Compounds which potentiate glutamate receptor and uses thereof in medicine |
| SI2607362T1 (sl) | 2005-02-17 | 2015-03-31 | Astellas Pharma Inc. | Piperidinski in piperazinski karboksilati kot FAAH inhibitorji |
| WO2006100591A1 (en) | 2005-03-25 | 2006-09-28 | Pharmacia & Upjohn Company Llc | 4-piperazinnylthieno [2,3-d] pyrimidine compounds as platelet aggregation inhibitors |
| JP2008534571A (ja) | 2005-03-28 | 2008-08-28 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 血小板凝集阻害物質としての４−ピペラジニルチエノ［２，３−ｄ］ピリミジン化合物 |
| JP2008534573A (ja) | 2005-03-28 | 2008-08-28 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 血小板凝集阻害剤としての４−ピペラジノチエノ［２，３−ｄ］ピリミジン化合物 |
| JP2008534570A (ja) | 2005-03-28 | 2008-08-28 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 血小板凝集阻害薬としての４−ピペラジニルチエノ［２，３−ｄ］ピリミジン化合物 |
| JP2009501235A (ja) | 2005-07-15 | 2009-01-15 | シェーリング コーポレイション | 癌処置において有用なキナゾリン誘導体 |
| TW200740779A (en) * | 2005-07-22 | 2007-11-01 | Mitsubishi Pharma Corp | Intermediate compound for synthesizing pharmaceutical agent and production method thereof |
| JP2009506987A (ja) | 2005-08-02 | 2009-02-19 | ニューロゲン コーポレイション | ジピペラジニルケトンおよび関連する類似体 |
| EP1948607B1 (en) * | 2005-09-16 | 2010-04-07 | Janssen Pharmaceutica, N.V. | Cyclopropyl amines as modulators of the histamine h3 receptor |
| US8158673B2 (en) | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
| MY151028A (en) | 2005-10-31 | 2014-03-31 | Janssen Pharmaceutica Nv | Novel processes for the preparation of cyclopropyl-amide derivatives |
| TW200740803A (en) | 2005-12-21 | 2007-11-01 | Vertex Pharma | Heterocyclic derivatives as modulators of ion channels |
| WO2007076140A2 (en) | 2005-12-23 | 2007-07-05 | University Of Cincinnati | Treatment methods employing histamine h3 receptor antagonists, including betahistine |
| AU2007204426A1 (en) * | 2006-01-13 | 2007-07-19 | F. Hoffmann-La Roche Ag | Cyclohexyl piperazinyl methanone derivatives and their use as histamine H3 receptor modulators |
| CN101384581B (zh) * | 2006-02-17 | 2013-09-18 | 弗·哈夫曼-拉罗切有限公司 | 作为5ht2/d3调节剂的苯甲酰基-哌啶衍生物 |
| MX2008011133A (es) | 2006-03-01 | 2008-12-18 | Cementech Pty Ltd | Matriz para elementos de albañileria y metodo de fabricacion de la misma. |
| JP2009132621A (ja) | 2006-03-13 | 2009-06-18 | Ajinomoto Co Inc | シクロプロピルアミド化合物の製造方法 |
| WO2007111921A1 (en) | 2006-03-23 | 2007-10-04 | Amgen Inc. | 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases |
| WO2007138928A1 (ja) | 2006-05-26 | 2007-12-06 | Kaneka Corporation | 光学活性３－アミノ－２－ヒドロキシプロピオン酸シクロプロピルアミド誘導体およびその塩の製造方法 |
| RU2449989C2 (ru) * | 2006-06-23 | 2012-05-10 | Эбботт Лэборетриз | Производные циклопропиламина в качестве модуляторов h3-гистаминового рецептора |
| US9108948B2 (en) | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
| AU2007271187A1 (en) | 2006-07-03 | 2008-01-10 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg | Fused bicyclic compounds interacting with the histamine H4 receptor |
| GB0615620D0 (en) * | 2006-08-05 | 2006-09-13 | Astrazeneca Ab | A process for the preparation of optically active intermediates |
| US20090247499A1 (en) * | 2006-08-21 | 2009-10-01 | Fletcher Joan M | Sulfonylated piperazines as cannabinoid-1 receptor modulators |
| TW200828371A (en) | 2006-09-21 | 2008-07-01 | Matsushita Electric Industrial Co Ltd | Chip-type filter |
| DE102006056526A1 (de) * | 2006-11-30 | 2008-06-05 | Archimica Gmbh | Verfahren zur stereoselektiven Synthese von chiralen Epoxiden durch ADH-Reduktion von alpha-Abgangsgruppen-substituierten Ketonen und Cyclisierung |
| US7737149B2 (en) | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
| WO2008147864A2 (en) | 2007-05-22 | 2008-12-04 | Xenon Pharmaceuticals Inc. | Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions |
| WO2008150364A1 (en) | 2007-05-23 | 2008-12-11 | Merck & Co., Inc. | Cyclopropyl pyrrolidine orexin receptor antagonists |
| DE602008002598D1 (en) | 2007-06-11 | 2010-10-28 | Hoffmann La Roche | Cyclohexylderivate |
| EP2253615B1 (en) * | 2007-08-22 | 2014-07-09 | AstraZeneca AB | Cyclopropyl amide derivatives |
| EP2207540B1 (en) * | 2007-10-04 | 2014-02-26 | F. Hoffmann-La Roche AG | Cyclopropyl aryl amide derivatives and uses thereof |
| CL2009000004A1 (es) | 2008-01-15 | 2010-02-19 | Lilly Co Eli | Forma cristalina de r-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida; composicion farmaceutica que comprende a dicha forma cristalina; y uso para el tratamiento de diabetes o hiperglicemia. |
| DE102008049371A1 (de) | 2008-03-06 | 2009-09-10 | Mühlbauer Ag | Einrichtung mit einem RFID-Transponder in einem elektrisch leitfähigen Gegenstand und Herstellungsverfahren hierfür |
| MX2010010242A (es) * | 2008-03-20 | 2010-12-06 | Forest Lab Holdings Ltd | Derivados novedosos de piperazina como inhibidores de la estearoil-coa desaturasa. |
| BRPI0913057A2 (pt) * | 2008-05-08 | 2015-10-13 | Evotec Ag | azetidinas e ciclobutanos como antagonistas de receptor de histamina h3 |
| US8586607B2 (en) | 2008-07-28 | 2013-11-19 | Syddansk Universitet | Compounds for the treatment of metabolic diseases |
| CN101462980B (zh) * | 2009-01-05 | 2013-01-09 | 扬州天辰精细化工有限公司 | 2，6—二氟苯甲酰胺的工业化生产方法 |
| TW201039825A (en) * | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
| US20110201623A1 (en) | 2010-02-18 | 2011-08-18 | Uczynski Michael A | Crystalline Form Of A Cyclopropyl Benzamide Derivative |
| JP5746718B2 (ja) * | 2010-02-18 | 2015-07-08 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | シクロプロピルアミド誘導体からなる固体形態 |
-
2011
- 2011-02-17 US US13/029,362 patent/US20110201623A1/en not_active Abandoned
- 2011-02-17 CA CA 2790040 patent/CA2790040A1/en not_active Abandoned
- 2011-02-17 AU AU2011218491A patent/AU2011218491C1/en not_active Ceased
- 2011-02-17 EP EP20110744974 patent/EP2536685B1/en not_active Not-in-force
- 2011-02-17 CN CN2011800196365A patent/CN102869651A/zh active Pending
- 2011-02-17 SG SG2012055240A patent/SG182732A1/en unknown
- 2011-02-17 MX MX2012009473A patent/MX2012009473A/es active IP Right Grant
- 2011-02-17 BR BR112012020629A patent/BR112012020629A2/pt not_active IP Right Cessation
- 2011-02-17 CA CA 2788444 patent/CA2788444A1/en not_active Abandoned
- 2011-02-17 RU RU2012136148/04A patent/RU2012136148A/ru not_active Application Discontinuation
- 2011-02-17 JP JP2012553849A patent/JP2013520413A/ja not_active Ceased
- 2011-02-17 EP EP11744975.1A patent/EP2536702A4/en not_active Withdrawn
- 2011-02-17 CN CN201180019632.7A patent/CN103168027B/zh not_active Expired - Fee Related
- 2011-02-17 MX MX2012009480A patent/MX336333B/es unknown
- 2011-02-17 TW TW100105296A patent/TWI520945B/zh not_active IP Right Cessation
- 2011-02-17 RU RU2012139082/04A patent/RU2012139082A/ru not_active Application Discontinuation
- 2011-02-17 ES ES11744974.4T patent/ES2541857T3/es active Active
- 2011-02-17 BR BR112012020782A patent/BR112012020782A2/pt not_active IP Right Cessation
- 2011-02-17 NZ NZ60211011A patent/NZ602110A/en not_active IP Right Cessation
- 2011-02-17 AR ARP110100485 patent/AR080204A1/es unknown
- 2011-02-17 WO PCT/SE2011/050171 patent/WO2011102794A1/en not_active Ceased
- 2011-02-17 JP JP2012553850A patent/JP2013520414A/ja active Pending
- 2011-02-17 SG SG10201501226VA patent/SG10201501226VA/en unknown
- 2011-02-17 SG SG2012059473A patent/SG183274A1/en unknown
- 2011-02-17 NZ NZ60192011A patent/NZ601920A/en not_active IP Right Cessation
- 2011-02-17 KR KR20127024174A patent/KR20130004296A/ko not_active Withdrawn
- 2011-02-17 KR KR20127021548A patent/KR20130002316A/ko not_active Withdrawn
- 2011-02-17 AR ARP110100486 patent/AR080205A1/es unknown
- 2011-02-17 WO PCT/SE2011/050172 patent/WO2011102795A1/en not_active Ceased
- 2011-02-17 TW TW100105300A patent/TWI494301B/zh not_active IP Right Cessation
- 2011-02-17 AU AU2011218492A patent/AU2011218492B2/en not_active Ceased
- 2011-02-17 US US13/579,605 patent/US9012452B2/en not_active Expired - Fee Related
-
2012
- 2012-08-13 IL IL221431A patent/IL221431A/en not_active IP Right Cessation
- 2012-08-16 CL CL2012002259A patent/CL2012002259A1/es unknown
- 2012-08-17 CO CO12140266A patent/CO6592109A2/es unknown
- 2012-08-17 CL CL2012002286A patent/CL2012002286A1/es unknown
-
2015
- 2015-08-14 JP JP2015160029A patent/JP2016006103A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20130004296A (ko) | 시클로프로필 아미드 유도체의 제조 방법 및 그와 관련된 중간체 | |
| KR102396059B1 (ko) | 신규 화합물 및 이의 제조방법 | |
| EP3297678B1 (en) | An improved processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof | |
| WO2012025944A2 (en) | Sitagliptin, salts and polymorphs thereof | |
| CN106316889A (zh) | 依度沙班中间体的制备方法 | |
| EP3280721B1 (en) | Process for preparation of nitrogen mustard derivatives | |
| RU2498976C2 (ru) | Усовершенствованный способ получения ингибитора дипептидилпептидазы-iv и промежуточного соединения | |
| ES2875411T3 (es) | Síntesis de trans-8-cloro-5-metil-1-[4-(piridin-2-iloxi)-ciclohexil]-5,6-dihidro-4h-2,3,5,10b-tetraazabenzo[e]azuleno y formas cristalinas del mismo | |
| CN101563329A (zh) | 用于制备4，4’-（1-甲基-1，2-乙二基）-双-（2，6-哌嗪二酮）的新方法 | |
| WO2011156355A1 (en) | Production method of phenyl guanidine salts and their intermediates | |
| KR102593038B1 (ko) | 알킬아민 유도체의 제조 방법 및 이의 제조 중간체 | |
| CN103664704A (zh) | 一种合成 n,n’-二取代基脲的方法 | |
| EP3892615A1 (en) | Process for the preparation of silodosin | |
| HK1178142B (en) | Processes for making cyclopropyl amide derivatives and intermediates associated therewith | |
| TW200403222A (en) | Process for the preparation of amino-pyrrolidine derivatives | |
| WO2005000810A1 (ja) | 含窒素複素環化合物の製造方法 | |
| CN110143947B (zh) | 一种色瑞替尼类似物的制备方法 | |
| Li | Investigation of the intramolecular Zwitterionic-1, 3-Diaza Claisen rearrangement to generate substituted cyclic guanidines via Co (II) catalyzed formation of allylamino-tethered carbodiimide | |
| HK1250732B (en) | Process for preparation of nitrogen mustard derivatives | |
| JP2008001611A (ja) | ３ｒ−アミノピロリジン誘導体の製造方法 | |
| JP2014185091A (ja) | ３−アミン−４−ピペリドン誘導体の製造方法 | |
| NZ759478B2 (en) | Synthesis of trans-8-chloro-5-methyl-1-[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulene and crystalline forms thereof | |
| EP2396334A1 (fr) | Derives de n-[(2-aza-bicyclo[2.1.1]hex-1-yl]-aryl-methyl]-benzamide, leur preparation et leur application en therapeutique | |
| EP2408763A2 (fr) | Derives de n-ý(2-aza-bicycloý2.1.1¨hex-1-yl)-aryl-methyl¨-heterobenzamide, leur preparation et leur application en therapeutique |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20120917 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |